Below you can find the list of 5 best genomic stocks to buy now according to hedge funds. For a detailed discussion as well as a more comprehensive list please see 12 Best Genomic Stocks To Buy Now.
5. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)
No of HFs: 35
Total Value of HF Holdings: $902 Million
Alnylam Pharmaceuticals, Inc. is ranked as the fifth-best genomic stock to buy now. The company is a biopharmaceutical company that focuses on the production and development of RNA interference therapeutics for genetically defined diseases.
Recently, the company announced the appointment of Tolga Tanguler formed Senior Vice President of Alexion as their Chief Commercial Officer where he will be leading the global marketing, sales, market access, commercial operations, and strategy for the company. John Maraganore, Ph.D., Chief Executive Officer of Alnylam mentioned,
“After an in-depth and comprehensive search, we have selected Tolga Tanguler, a dynamic and highly skilled commercial leader to join Alnylam. With over 20 years of global pharmaceutical and biotech experience, most recently at Pfizer and Alexion, Tolga’s considerable success commercializing multiple rare, specialty and common disease products positions him as an excellent choice for this key role. With Tolga, Kasha, Salil and Aggie joining Alnylam, we have now rounded out our world-class leadership team across our commercial, medical and compliance expertise areas. Together, these outstanding leaders stand poised to support the ongoing global launches of our three marketed products and promising pipeline of innovative medicines addressing a range of patient needs, while we continue on our path towards profitability.”